HMN 2025: How Bronchoscopic lung-biopsy methods can match percutaneous approaches for complete biomarker testing

A multidisciplinary guideline panel convened by the American Association of Bronchology and Interventional Pulmonology (AABIP) and the Early Detection & Screening Committee of the International Association for the Study of Lung Cancer (IASLC) has decided that guided-bronchoscopy sampling supplies tissue of comparable adequacy for complete biomarker testing to percutaneous (CT-guided) biopsy, whereas delivering a superior security profile—particularly when up to date navigational applied sciences are employed.

The tips have been published within the Journal of Thoracic Oncology.

Linear endobronchial guided sampling of accessible mediastinal lesions is properly established as a first-choice modality for lung cancer mediastinal staging. Parenchymal lung lesions, nevertheless, are routinely accessed by both a percutaneous (CT-guided) or a bronchoscopic method.

Direct comparisons between the percutaneous method and bronchoscopy or endobronchial ultrasound (EBUS) and mediastinoscopy are sparse in regard to diagnostic accuracy, and it stays unknown which sampling approach is the most secure and gives essentially the most enough materials for complete biomarker testing.

This medical practice guideline developed by AABIP and IASLC supplies proof on the security and sampling adequacy for complete biomarker testing of bronchoscopy-guided lung parenchymal biopsies as in comparison with percutaneous biopsies, and endobronchial ultrasound-guided lymph node sampling as in comparison with mediastinoscopy.

The out there proof means that guided-bronchoscopy sampling is of comparable adequacy for complete biomarker testing in comparison with percutaneous biopsy, whereas persistently demonstrating a greater security profile with fewer issues, particularly with the usage of up to date superior navigational bronchoscopic applied sciences.

Key findings embody:

• Sampling adequacy: Across the analyzed research, bronchoscopy-guided parenchymal biopsies yielded molecular-testing specimens equal in high quality and amount to these obtained by way of percutaneous biopsy.
• Safety: Guided bronchoscopy persistently produced fewer severe issues—comparable to pneumothorax and vital bleeding—than percutaneous approaches.
• Lymph-node staging: Endobronchial ultrasound (EBUS) continues to rival mediastinoscopy in diagnostic accuracy whereas providing decrease morbidity for mediastinal evaluation.

“These suggestions are instantly actionable for clinicians deciding how finest to acquire tissue for biomarker evaluation in suspected or confirmed lung cancer,” stated Abhinav Agrawal, MD, Director of Interventional Pulmonology and Associate Professor of Medicine & Cardiovascular/Thoracic Surgery on the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

“They must also inform the design of future medical trials by highlighting each pattern adequacy and the security benefits of minimally invasive bronchoscopic methods.”

Provided by
International Association for the Study of Lung Cancer